Fig. 3
From: Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
Shows the Forest Plot indicating the iDFS hazard ratio for Palbociclib plus endocrine therapy versus endocrine therapy alone within prespecified subgroups in the PALLAS trial